Prothena Corporation plc Ordinary Shares - PRTA STOCK NEWS

Welcome to our dedicated page for Prothena Corporation plc Ordinary Shares news (Ticker: PRTA), a resource for investors and traders seeking the latest updates and insights on Prothena Corporation plc Ordinary Shares stock.

Prothena Corporation plc (NASDAQ: PRTA) is a leading biotechnology company dedicated to the discovery, development, and commercialization of novel protein immunotherapies. These therapies aim to treat diseases involving amyloid or cell adhesion. Prothena's core business focuses on developing therapeutic monoclonal antibodies that target disease-causing proteins.

The company's investigational therapeutics are designed to address various serious conditions. Prothena's product candidates target a range of indications, including:

Amyloid Light-chain (AL) amyloidosis (NEOD001): Currently in a global Phase 3 registration clinical trial, known as the VITAL Amyloidosis Study. Additionally, there is an ongoing Phase 1/2 trial.
Parkinson’s disease and other synucleinopathies (PRX002): Undergoing a Phase 1 multiple ascending dose clinical trial.
Psoriasis and other inflammatory diseases (PRX003): In a Phase 1 single ascending dose clinical trial.

Prothena’s lead program, NEOD001, is aimed at treating AL amyloidosis, a serious condition that affects the organs. PRX002 and PRX003 are also significant as they target critical unmet needs in neurodegenerative and inflammatory diseases.

The company’s strategy is underpinned by a robust scientific approach and a pipeline of promising candidates. Prothena is led by an elite team with a proven track record in biotechnology and pharmaceuticals, working tirelessly to bring breakthrough therapies to market.

Financially, Prothena is in a strong position, bolstered by strategic partnerships and a focus on high-potential therapeutic areas. The company continues to advance its clinical programs while exploring new avenues for growth and innovation.

Latest News: Stay updated with the most recent developments and updates from Prothena Corporation plc.

04/15/2024 04:05 PM

News

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Rhea-AI Summary

Prothena plc (NASDAQ:PRTA) announces the publication on the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential anti-amyloid treatment for AL amyloidosis. The publication in Leukemia & Lymphoma highlights birtamimab's ability to clear amyloid deposits in vital organs, showing a significant survival benefit in patients with Mayo Stage IV AL amyloidosis.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.96%

Tags

03/05/2024 04:05 PM

News

Prothena to Participate in Upcoming Healthcare Conferences

Rhea-AI Summary

Prothena Corporation plc (PRTA) announced senior management's participation in upcoming investor conferences. The company will be present at Leerink Partners Global Biopharma Conference on March 12 and Jefferies Biotech on the Bay Summit on March 13. A webcast of the fireside chat will be available on the company's website.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.49%

Tags

03/04/2024 04:05 PM

News

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Rhea-AI Summary

Prothena Corporation plc (PRTA) appoints David Ford as Chief People Officer to drive human resources strategy and company growth. Ford brings over 25 years of HR experience, transitioning Prothena to a commercially successful entity.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.11%

Tags

02/21/2024 04:05 PM

News

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Rhea-AI Summary

Prothena Corporation plc (NASDAQ:PRTA) appoints Daniel G. Welch as an independent director and Chair Designate. The company plans a transition in leadership with Dr. Lars Ekman stepping down as Chair. Mr. Welch's vast industry experience aims to guide Prothena through a transformative phase in advancing neurodegenerative and rare peripheral amyloid disease therapies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.37%

Tags

02/15/2024 04:05 PM

News

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Rhea-AI Summary

Prothena Corporation plc (PRTA) reported a net loss of $67.5 million for Q4 2023 and $147.0 million for the full year. The company expects to end 2024 with approximately $405 million in cash. Significant advancements were made in the Alzheimer’s disease portfolio, with promising Phase 1 clinical trial data for PRX012 and FDA clearances for PRX123. Prothena also received a $55 million milestone payment from Bristol Myers Squibb. The company's financials show an increase in R&D and G&A expenses compared to the previous year.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.75%

Tags

02/08/2024 04:05 PM

News

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Rhea-AI Summary

Prothena Corporation plc (PRTA) will report its Q4 and full year 2023 financial results on February 15, 2024, followed by a live audio conference call. The call will be available via the Company's website and a replay will be accessible for at least 90 days. Dial-in information for accessing the call and the replay is provided in the announcement.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.46%

Tags

01/08/2024 08:30 AM

News

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Rhea-AI Summary

Prothena Corporation plc (PRTA) provided a business update on its late-stage clinical biotechnology programs. The company remains well financed with approximately $621 million in cash, cash equivalents, and restricted cash at year end 2023. Key updates include progress on PRX012 and PRX123 for Alzheimer’s disease, and on birtamimab for AL amyloidosis treatment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-13.23%

Tags

11/02/2023 04:05 PM

News

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Rhea-AI Summary

Prothena Corporation reported financial results for Q3 and first nine months of 2023. Net cash provided by operating and investing activities was $9.1 million in Q3 and net cash used was $84.1 million for the first nine months. Quarter-end cash position was $673.1 million. Received $55 million payment from Bristol Myers Squibb for exclusive worldwide license to PRX005. Expect to deliver upcoming clinical milestones in the next 15 months.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.41%

Tags

10/26/2023 04:05 PM

News

Prothena to Report Third Quarter 2023 Financial Results on November 2

Rhea-AI Summary

Prothena Corporation to report Q3 and 9M 2023 financial results on November 2

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.52%

Tags

08/31/2023 04:05 PM

News

Prothena to Participate in Upcoming Healthcare Conferences

Rhea-AI Summary

Prothena Corporation plc to participate in upcoming investor conferences

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.41%

Tags

FAQ

What is the current stock price of Prothena Corporation plc Ordinary Shares (PRTA)?

The current stock price of Prothena Corporation plc Ordinary Shares (PRTA) is $11.95 as of December 18, 2024.

What is the market cap of Prothena Corporation plc Ordinary Shares (PRTA)?

The market cap of Prothena Corporation plc Ordinary Shares (PRTA) is approximately 634.5M.

What is the primary focus of Prothena Corporation plc?

Prothena focuses on the discovery, development, and commercialization of novel protein immunotherapies for diseases involving amyloid or cell adhesion.

What are the main indications Prothena's products target?

Prothena's product candidates target AL amyloidosis (NEOD001), Parkinson’s disease (PRX002), and inflammatory diseases like psoriasis (PRX003).

What is NEOD001?

NEOD001 is Prothena's lead program aimed at treating AL amyloidosis. It is currently in a global Phase 3 registration clinical trial, the VITAL Amyloidosis Study.

Which clinical trials are PRX002 and PRX003 undergoing?

PRX002 is in a Phase 1 multiple ascending dose clinical trial, while PRX003 is in a Phase 1 single ascending dose clinical trial.

What makes Prothena's approach unique?

Prothena's approach is unique due to its focus on monoclonal antibodies targeting disease-causing proteins, a robust scientific strategy, and a team with a proven track record.

How is Prothena financially positioned?

Prothena is financially strong, supported by strategic partnerships and a dedicated focus on high-potential therapeutic areas.

Who leads Prothena Corporation plc?

Prothena is led by an elite team with recognized expertise and a successful track record in biotechnology and pharmaceuticals.

What is the VITAL Amyloidosis Study?

The VITAL Amyloidosis Study is a global Phase 3 registration clinical trial for Prothena's lead program, NEOD001, aimed at treating AL amyloidosis.

How does Prothena contribute to treating Parkinson's disease?

Prothena is developing PRX002, a monoclonal antibody targeting synucleinopathies, including Parkinson’s disease, currently in a Phase 1 clinical trial.